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Introduction: Type-2 diabetes (T2D) is a modern global epidemic associated with multiple 
health complications and economic burden. Exercise improves glycaemic control in 
populations with T2D with greater insulin sensitivity, muscle hypertrophy, and reduced 
emotional distress as possible mediators. Milk protein supplementation has been shown to 
produce similar benefits, raising the potential of an adjunct therapy. Therefore, the primary 
purpose of the thesis was to determine if whey-protein supplementation can promote skeletal 
muscle plasticity associated with improved glycaemic control in exercising men with T2D. 
Secondary aims were to determine if improvements in functional capacity and glycaemic 
control led to better mood and quality of life. 
Methods: In a randomized, double blind clinical trial, 24 non-insulin dependent middle-aged 
men with T2D were allocated to a pre- and post-training whey-carbohydrate (20 grams-10 
grams) supplement or isocaloric carbohydrate-only control. Participants completed 45 high-
intensity endurance and resistance exercise sessions over 10 weeks. Insulin sensitivity was 
determined from glucose disposal rates (GDR) during a euglycaemic insulin clamp, with 
fasting blood glucose concentration (FBG) and the homeostatic model of assessment of 
insulin resistance (HOMA-IR) providing secondary measures of glycaemic control. Insulin-
mediated haemodynamics; microvascular blood flow (mBF) and microvascular blood volume 
(mBV) were assessed at the vastus lateralis (VL) muscle via near-infrared spectroscopy. VL 
muscle biopsies were used to determine capillarity, intramyofibrillar mitochondrial and lipid 
density, citrate synthase (CS) and cytochrome c oxidase (COX) activity, and mRNA content 
of angiogenic and mitochondrial markers: eNOS, VEGFA, VEGFR2, PGC1-α, CS, NRF1. 
Aerobic capacity (VO2peak), strength (1-repetition maximum), VL muscle and subcutaneous 
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adipose thickness, and survey-rated mood and quality of life (DASS42; SF-36) were also 
assessed.  
Results: There were substantial increases in GDR (27.5%; 90%CI 1.2%, 60.7% and 24.8%; -
5.4%, 64.8%), capillarisation (24.5%; -0.1%, 55.0 and 26.3%; 1.9%, 56.6%), and 
mitochondrial density (24.3%; 13.8%, 35.8% and 26.7%; 16.8%, 37.5%) in the control and 
whey groups respectively, with no group differences. Lipid density, COX enzyme activity, 
VL muscle thickness, VO2peak, 1RM strength, mood, and quality of life were also 
substantially increased with no group differences. Exercise training had no effect on 
microvascular haemodynamics; however, whey supplementation produced likely and 
possible improvements in mBV (16.8%; -4.3%, 42.6%) and mBF (5.9%; -3.7%, 16.3%) 
respectively at rest and likely improvements in both mBV (17.5%; -3.7%, 43.5%) and mBF 
(10.2%; 0.3%, 21.1%) under insulin-stimulated conditions. Regression analysis of the pooled 
10-week change outcomes showed a positive relationship between the change in lipid density 
and the change in GDR (r = 0.29); negative associations between basal mBV and FBG 
(r=.27) and HOMA-IR (r=.30); a negative association between basal mBF and HOMA-IR 
(r=.48); and a positive association (r = 0.39) between the total DASS score and the change in 
FBG. 
Conclusion: Peri-training whey protein supplementation elevated microvascular blood 
kinetics in middle-aged men with T2D; but did not accentuate the substantial improvements 
produced by the intense mixed-mode exercise training on tissue and cellular remodelling, 
insulin sensitivity,  glycaemia, exercise capacity, mood or quality of life. The findings 
support the use of adjunct whey protein supplementation for elevating microvascular blood 
kinetics in populations with T2D, an outcome that could potentially improve the treatment of 
vascular diseases where microcirculation contributes to disease pathology and therefore 
warrants further exploration. The observation that myocellular lipid density was increased by 
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intense exercise training and not detrimental to insulin sensitivity supports recent evidence 
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